Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew K Robinson

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|September 17, 2011
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerRanee Mehra, Ilya G Serebriiskii, Roland L Dunbrack, et al.
Molecular Cancer Therapeutics|August 25, 2006
Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancerQing-an Yuan, Heidi H Simmons, Matthew K Robinson, et al.
Mabs|September 5, 2015
Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approachAndreas Lehmann, Josephine H F Wixted, Maxim V Shapovalov, et al.
Plos One|November 12, 2014
Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodiesJimson W D'Souza, Smitha Reddy, Lisa E Goldsmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2010
Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatmentSmitha Reddy, Calvin C Shaller, Mohan Doss, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2016
Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET RadiotracersJimson W D'Souza, Harvey Hensley, Mohan Doss, et al.
ACS Nano|May 12, 2012
Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkersMitchell B Lerner, Jimson D'Souza, Tatiana Pazina, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 3, 2012
Impact of expression system on the function of the C6.5 diabody PET radiotracerJoshua Miller, Mohan Doss, Ryan McQuillen, et al.
Cancer Research|March 1, 2005
Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabodyMatthew K Robinson, Mohan Doss, Calvin Shaller, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 6, 2004
Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scannerDinko E González Trotter, Ravindra M Manjeshwar, Mohan Doss, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|September 17, 2011
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerRanee Mehra, Ilya G Serebriiskii, Roland L Dunbrack, et al.
Molecular Cancer Therapeutics|August 25, 2006
Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancerQing-an Yuan, Heidi H Simmons, Matthew K Robinson, et al.
Mabs|September 5, 2015
Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approachAndreas Lehmann, Josephine H F Wixted, Maxim V Shapovalov, et al.
Plos One|November 12, 2014
Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodiesJimson W D'Souza, Smitha Reddy, Lisa E Goldsmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2010
Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatmentSmitha Reddy, Calvin C Shaller, Mohan Doss, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2016
Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET RadiotracersJimson W D'Souza, Harvey Hensley, Mohan Doss, et al.
ACS Nano|May 12, 2012
Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkersMitchell B Lerner, Jimson D'Souza, Tatiana Pazina, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 3, 2012
Impact of expression system on the function of the C6.5 diabody PET radiotracerJoshua Miller, Mohan Doss, Ryan McQuillen, et al.
Cancer Research|March 1, 2005
Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabodyMatthew K Robinson, Mohan Doss, Calvin Shaller, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 6, 2004
Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scannerDinko E González Trotter, Ravindra M Manjeshwar, Mohan Doss, et al.
Pageof 3